Janux Therapeutics, Inc. continues its focus on novel immunotherapies targeting solid tumors, advancing clinical candidates JANX007 and JANX008 with supportive interim data in prostate cancer and multiple solid tumors. The company’s recent exclusive collaboration with Bristol-Myers Squibb (BMS) provides a significant financial and development partnership centered on a validated solid tumor antigen therapeutic, underpinning future growth prospects. Despite promising clinical progress, Janux’s financials reveal expanding operating losses and negative cash flows as expected for a clinical-stage entity still early in its commercialization journey.